Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus intravenous palonosetron for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting
2005-000137-37Phase 3Completed
- Sponsor
- Helsinn
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV) (4 arms), sponsored by Helsinn. Primary endpoint: Complete response during 0-24 hours. Started Aug 2005; status: completed.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2005-000137-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000137-37.